

Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Melatonin Extended Release 2 mg tablets.

“The addition of Melatonin ER is adding a new partnership with a European producer which can be used to source additional new products. This is our fourth new partnership within a couple of weeks which have in total granted us access to more than 10 new products.” says Mr Lars Minor CEO of Newbury

Regulatory filling of Melatonin ER 2 mg will take place in the near future and launch of this medicine is planned in the Nordics where the total annual value of the market is estimated to be 11 MEUR according to DLMI Nordic Pharma Insights.

Melatonin ER is used on its own for the short-term treatment of primary insomnia (poor quality of sleep) in patients aged 55 years or over. Older people may produce less melatonin, leading to the development of insomnia. By replacing the hormone, Melatonin ER increases blood levels of melatonin, helping people to sleep. Because Melatonin ER tablets release melatonin slowly over a few hours, they mimic the natural production of melatonin in the body.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
20 October 2023 08:00:00 CEST



Attachments

[Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg](#)